Article

Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats

Department of Bioengineering, University of California, San Diego, CA, USA.
AJP Endocrinology and Metabolism (Impact Factor: 4.09). 10/2010; 300(1):E164-74. DOI: 10.1152/ajpendo.00219.2010
Source: PubMed

ABSTRACT Peroxisome proliferator-activated receptor-γ (PPARγ) ligands, including the insulin-sensitizing thiazolidinedione drugs, transcriptionally regulate hundreds of genes. Little is known about the relationship between PPARγ ligand-specific modulation of cellular mechanisms and insulin sensitization. We characterized the insulin sensitivity and multitissue gene expression profiles of lean and insulin-resistant, obese Zucker rats untreated or treated with one of four PPARγ ligands (pioglitazone, rosiglitazone, troglitazone, and AG-035029). We analyzed the transcriptional profiles of adipose tissue, skeletal muscle, and liver from the rats and determined whether ligand treatment insulin-sensitizing potency was related to ligand treatment-induced alteration of functional pathways. Ligand treatments improved insulin sensitivity in obese rats to varying degrees. Adipose tissue profiles revealed ligand treatment-selective modulation of inflammatory and branched-chain amino acid (BCAA) metabolic pathways, which correlated with ligand treatment-specific insulin-sensitizing potency. Skeletal muscle profiles showed that obese rats exhibited elevated expression of adipocyte and slow-twitch fiber markers, which further increased after ligand treatment, but the magnitude of the treatment-induced changes was not correlated with insulin sensitization. Although PPARγ ligand treatments heterogeneously improved dysregulated expression of cholesterol and fatty acid biosynthetic pathways in obese rat liver, these alterations were not correlated with ligand insulin-sensitizing potency. PPARγ ligand treatment-specific insulin-sensitizing potency correlated with modulation of adipose tissue inflammatory and BCAA metabolic pathways, suggesting a functional relationship between these pathways and whole body insulin sensitivity. Other PPARγ ligand treatment-induced functional pathway changes were detected in adipose tissue, skeletal muscle, and liver profiles but were not related to degree of insulin sensitization.

0 Followers
 · 
114 Views
  • Source
    • "Sibutramine had previously been used as an appetite suppressant but has been withdrawn from the market due to an increased risk of psychiatric disorders and non-fatal myocardial infarction or stroke (Kang and Park 2012). The peroxisome proliferator-activated receptor-c (PPAR-c) agonistic thiazolidinediones (pioglitazone and rosiglitazone) may be an alternative option to improve insulin sensitivity (Hsiao et al. 2011; Pita et al. 2012). Moreover, fibrates, as PPARa agonists, decrease TG levels by 23–80 %, and LDL-C levels by up to 38–80 % (Millar et al. 2009; Srivastava 2011; Zaborska et al. 2000). "
    [Show abstract] [Hide abstract]
    ABSTRACT: tert-Butylhydroquinone (tBHQ) is a commonly used antioxidant additive that is approved for human use by both the Food and Agriculture Organization and the World Health Organization (FAO/WHO). In this study, we examined the effect of tBHQ on body weight gain and found that food supplementation with 0.001 % (w/w) tBHQ inhibited 61.4 % (P < 0.01) of body weight gain in high-fat diet (HFD)-induced C57BL/6 mice, and the oral administration of tBHQ (1.5 mg/kg) reduced 47.5 % (P < 0.05) of body weight gain in normal diet fed db/db mice. The HFD increased lipid deposit in adipocytes, but these were reduced significantly by tBHQ treatment in C57BL/6 mice. tBHQ supplementation significantly lowered the plasma triglyceride and total cholesterol, with reduced size of accumulated fat mass. The rate limiting enzyme of beta-oxidation (ACOX1) was significantly over-expressed in the liver with tBHQ treatment. These results indicate that tBHQ suppresses body weight gain in mice, possibly at least related to the up-regulation of ACOX1 gene expression.
    Archives of Pharmacal Research 04/2013; DOI:10.1007/s12272-013-0109-3 · 1.75 Impact Factor
  • Source
    • "(d) In KK/HIJ mice treated with RS, obvious mesangial matrix accumulation and diffuse collagen staining within renal tissues were observed (Masson trichrome, 400x). expression levels of hepatic PPAR-γ protein, which has been shown to correlate well with insulin sensitivity in several animal models [23] [24] [25]. One possible reason for the lack of effect could be that the ethanol extract from CS might contain several other non-polysaccharide components that could play an important role in inducing the previously observed hypoglycemic effects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus is the most common chronic disease in the world, and a wide range of drugs, including Chinese herbs, have been evaluated for the treatment of associated metabolic disorders. This study investigated the potential hypoglycemic and renoprotective effects of an extract from the solid-state fermented mycelium of Cordyceps sinensis (CS). We employed the KK/HIJ diabetic mouse model, in which the mice were provided with a high-fat diet for 8 weeks to induce hyperglycemia, followed by the administration of CS or rosiglitazone for 4 consecutive weeks. Several parameters were evaluated, including changes in body weight, plasma lipid profiles, oral glucose tolerance tests, insulin tolerance tests, and plasma insulin concentrations. Our results show that the CS extract significantly elevated HDL/LDL ratios at 4 weeks and decreased body weight gain at 8 weeks. Interestingly, CS treatment did not lead to obvious improvements in hyperglycemia or resistance to insulin, while in vitro MTT assays indicated that CS protects pancreatic beta cells against the toxic effects of STZ. CS also enhanced renal NKA activity and reduced the accumulation of mesangial matrix and collagen deposition. In conclusion, CS extract can potentially preserve β-cell function and offer renoprotection, which may afford a promising therapy for DM.
    Evidence-based Complementary and Alternative Medicine 02/2012; 2012:743107. DOI:10.1155/2012/743107 · 1.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Insulin resistance (IR) is a key pathological feature of metabolic syndrome and subsequently causes serious health problems with an increased risk of several common metabolic disorders. IR related metabolic disturbance is not restricted to carbohydrates but impacts global metabolic network. Branched-chain amino acids (BCAAs), namely valine, leucine and isoleucine, are among the nine essential amino acids, accounting for 35% of the essential amino acids in muscle proteins and 40% of the preformed amino acids required by mammals. The BCAAs are particularly responsive to the inhibitory insulin action on amino acid release by skeletal muscle and their metabolism is profoundly altered in insulin resistant conditions and/or insulin deficiency. Although increased circulating BCAA concentration in insulin resistant conditions has been noted for many years and BCAAs have been reported to be involved in the regulation of glucose homeostasis and body weight, it is only recently that BCAAs are found to be closely associated with IR. This review will focus on the recent findings on BCAAs from both epidemic and mechanistic studies.
    02/2013; 7(1). DOI:10.1007/s11684-013-0255-5
Show more